Samsung BioLogics Co (XKRX:207940) Debt-to-Equity

: 0.19 (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

Samsung BioLogics Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₩1,531,936 Mil. Samsung BioLogics Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₩377,397 Mil. Samsung BioLogics Co's Total Stockholders Equity for the quarter that ended in Dec. 2023 was ₩9,830,492 Mil. Samsung BioLogics Co's debt to equity for the quarter that ended in Dec. 2023 was 0.19.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Samsung BioLogics Co's Debt-to-Equity or its related term are showing as below:

XKRX:207940' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.14 Med: 0.21 Max: 0.8
Current: 0.19

During the past 10 years, the highest Debt-to-Equity Ratio of Samsung BioLogics Co was 0.80. The lowest was 0.14. And the median was 0.21.

XKRX:207940's Debt-to-Equity is ranked worse than
55.27% of 1073 companies
in the Biotechnology industry
Industry Median: 0.14 vs XKRX:207940: 0.19

Samsung BioLogics Co Debt-to-Equity Historical Data

The historical data trend for Samsung BioLogics Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Samsung BioLogics Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

0.15

0.17

0.26

0.28

0.19

Samsung BioLogics Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity																0.28	0.27	0.25	0.23	0.19

Competitive Comparison

For the Biotechnology subindustry, Samsung BioLogics Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Samsung BioLogics Co Debt-to-Equity Distribution

For the Biotechnology industry and Healthcare sector, Samsung BioLogics Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Samsung BioLogics Co's Debt-to-Equity falls into.

Samsung BioLogics Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Samsung BioLogics Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1531935.793	+	377396.784)	/	9830492.412
	=	0.19

Samsung BioLogics Co's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1531935.793	+	377396.784)	/	9830492.412
	=	0.19

Samsung BioLogics Co (XKRX:207940) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Samsung BioLogics Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Samsung BioLogics Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Samsung BioLogics Co (XKRX:207940) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Samsung BioLogics Co Ltd (XKRX:207940) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

125, Cheomdan-daero, Yeonsu-gu,, Incheon, KOR

Website

https://www.samsungbiologics.com

Samsung BioLogics Co Ltd engaged in development and manufacturing of bio-healthcare products.The Company works namely in Process Development, cGMP Manufacturing, Aseptic Fill and Finish.

Samsung BioLogics Co (XKRX:207940) Headlines

No Headlines